Better Discount To Bylvay £255,000 List Price Sways England’s NICE
Executive Summary
Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.
You may also be interested in...
Scottish HTA Requests More Data For Orphan Drugs
The SMC, Scotland’s health technology appraisal body, wants more data for Albireo Pharma’s ultra-orphan Bylvay and Novartis’s rare disease drug Adakveo.
New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval
Health technology assessment body NICE has also issued guidances rejecting three products.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.